The gain of methylation on the maternal allele results in the repression of H19 from the maternal allele leading to biallelic expression of IGF2. This epimutation occurs in 2–10% of BWS patients and is highly associated with tumor development [9,16,23]. This evidence concerns the gene IGF2 and Beckwith-Wiedemann syndrome.